Hematological response in patients with paroxysmal nocturnal hemoglobinuria treated with C5-inhibitor
Background. Paroxysmal nocturnal hemoglobinuria is a rare clonal disease of the hematopoietic system, with the key manifestations of hemolytic anemia, a high thrombosis rate, and bone marrow failure. Despite the high efficacy of C5‑inhibitors in intravascular hemolysis cessation, a significant propo...
Saved in:
Main Authors: | V. D. Latyshev, Z. T. Fidarova, R. V. Ponomarev, N. V. Tsvetaeva, E. A. Mikhaylova, E. A. Lukina, E. N. Parovichnikova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2024-01-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/900 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary
by: Celso Arrais, et al.
Published: (2025-07-01) -
Treatment of paroxysmal nocturnal hemoglobinuria
by: I. A. Lisukov, et al.
Published: (2014-07-01) -
National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria
by: A. D. Kulagin, et al.
Published: (2014-09-01) -
Classic paroxysmal nocturnal hemoglobinuria: A puzzling case of hemolytic anemia without cytopenia
by: Majed Abdul Basit Momin, et al.
Published: (2025-01-01) -
Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy
by: M. V. Marchenko, et al.
Published: (2024-09-01)